ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESR44

A Uniquely Scalable Platform for Sequencing Tens of Millions of Single Cells from Complex Clinical Samples with a Streamlined Workflow

Active
Institution
SANSIMEON, INC, CA
Principal investigator
Philipp Stefan Spuhler
Funding
$938K
Duration
2023–2027

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY/ABSTRACT Single-cell sequencing (SC-seq) has revolutionized our understanding of cellular heterogeneity, gene expression, and disease mechanisms. However, its adoption in clinical and translational research remains limited due to throughput constraints, complex workflows, and sample preparation biases. Sansimeon is addressing these limitations by developing a high- throughput, streamlined platform for scalable single-cell sequencing. This innovative system integrates automated workflow for direct analysis of peripheral whole blood and dissociated tissue. Our goal is to deliver an end-to-end solution capable of processing large-scale single cell experiments, with applications in diagnostics, rare cell detection, drug discovery, and cancer therapy development. We leverage novel microfluidic technologies to achieve unmatched throughput and data fidelity while preserving cells’ native states. The project will validate this system in clinically relevant samples and optimize its computational tools to support scaled single- cell datasets. These efforts aim to advance clinical research and accelerate the adoption of single- cell sequencing in healthcare and drug development.

LOADING MOONBASE SCORE

R44NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESSpecial Emphasis Panel[ZGM1 BBCB-W (SB)]throughputsinglestreamlinedsequencingsingle-cell sequencingsingle-cellsingle cellworkflow

Questions for Sansimeon, Inc

Sansimeon, Inc hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.

Same topic, scored first.